Literature DB >> 25469243

Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.

Yang Zou1, Mei-Zhen Huang2, Fa-Ying Liu1, Bi-Cheng Yang3, Li-Qun Wang3, Feng Wang1, Xiao-Hong Yu4, Lei Wan3, Xi-DI Wan3, Xiao-Yun Xu2, Wei Li2, Ou-Ping Huang1, Ming He5.   

Abstract

Cancer is caused by multiple genetic alterations within cells. Recently, large-scale sequencing has identified frequent ribonuclease type III (DICER1), CCCTC-binding factor (CTCF), ribosomal protein L22 (RPL22), DNA (cytosine-5-)-methyltransferase 3α (DNMT3A), transformation/transcription domain-associated protein (TRRAP), isocitrate dehydrogenase (IDH)1 and IDH2 hotspot mutations in diverse types of cancer. However, it remains largely unknown whether these mutations also exist in ovarian carcinomas. In the present study, a collection of 251 patients with distinct subtypes of ovarian carcinomas were recruited and sequenced for the presence of these hotspot mutations. However, no mutations in the seven genes were detected in the samples. These negative results, together with certain recent reports, indicate that the hotspot mutations in the CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 genes may not be actively involved in the carcinogenesis of ovarian carcinoma. Of note, the DICER1 mutation frequency in Sertoli-Leydig cell tumor in the present study was significantly lower compared to prior observation, and therefore, it is speculated that this discrepancy may be mainly due to the small sample size analyzed in the study. In addition, among these samples, frequent polymerase (DNA directed) ε, catalytic subunit (POLE1) and ring finger protein 43 (RNF43) mutations were identified in endometrioid and mucinous ovarian carcinomas, respectively; thus DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations may not play synergistic roles with POLE1 or RNF43 mutations in the carcinogenesis of endometrioid or mucinous ovarian carcinomas.

Entities:  

Keywords:  absence; hotspot mutations; ovarian carcinoma

Year:  2014        PMID: 25469243      PMCID: PMC4251111          DOI: 10.3892/br.2014.378

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  39 in total

1.  Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Authors:  Alireza Heravi-Moussavi; Michael S Anglesio; S-W Grace Cheng; Janine Senz; Winnie Yang; Leah Prentice; Anthony P Fejes; Christine Chow; Alicia Tone; Steve E Kalloger; Nancy Hamel; Andrew Roth; Gavin Ha; Adrian N C Wan; Sarah Maines-Bandiera; Clara Salamanca; Barbara Pasini; Blaise A Clarke; Anna F Lee; Cheng-Han Lee; Chengquan Zhao; Robert H Young; Samuel A Aparicio; Poul H B Sorensen; Michelle M M Woo; Niki Boyd; Steven J M Jones; Martin Hirst; Marco A Marra; Blake Gilks; Sohrab P Shah; William D Foulkes; Gregg B Morin; David G Huntsman
Journal:  N Engl J Med       Date:  2011-12-21       Impact factor: 91.245

2.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

Review 3.  Targeted therapies: how personal should we go?

Authors:  Miriam Martini; Loredana Vecchione; Salvatore Siena; Sabine Tejpar; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2011-11-15       Impact factor: 66.675

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers.

Authors:  Min S Kim; Yoo R Kim; Nam J Yoo; Sug H Lee
Journal:  APMIS       Date:  2012-07-03       Impact factor: 3.205

7.  RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.

Authors:  Georgina L Ryland; Sally M Hunter; Maria A Doyle; Simone M Rowley; Michael Christie; Prue E Allan; David D L Bowtell; Kylie L Gorringe; Ian G Campbell
Journal:  J Pathol       Date:  2013-02       Impact factor: 7.996

8.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.

Authors:  Mi Ran Kang; Min Sung Kim; Ji Eun Oh; Yoo Ri Kim; Sang Yong Song; Seong Il Seo; Ji Youl Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

9.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.

Authors:  Israel Zighelboim; David G Mutch; Amy Knapp; Li Ding; Mingchao Xie; David E Cohn; Paul J Goodfellow
Journal:  Hum Mutat       Date:  2014-01       Impact factor: 4.878

View more
  4 in total

Review 1.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

Review 2.  Aberrant expression and functions of protocadherins in human malignant tumors.

Authors:  Ming Shan; Yonghui Su; Wenli Kang; Ruixin Gao; Xiaobo Li; Guoqiang Zhang
Journal:  Tumour Biol       Date:  2016-07-24

Review 3.  Spectrum of DICER1 Germline Pathogenic Variants in Ovarian Sertoli-Leydig Cell Tumor.

Authors:  Elisa De Paolis; Rosa Maria Paragliola; Paola Concolino
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

4.  RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance.

Authors:  Shuyun Rao; Suraj Peri; Jens Hoffmann; Kathy Q Cai; Bryan Harris; Michele Rhodes; Denise C Connolly; Joseph R Testa; David L Wiest
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.